Article

Perceptions and priorities of owners of dogs with heart disease regarding quality versus quantity of life for their pets.

Department of Clinical Studies-Philadelphia, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Journal of the American Veterinary Medical Association (Impact Factor: 1.67). 08/2008; 233(1):104-8. DOI: 10.2460/javma.233.1.104
Source: PubMed

ABSTRACT To describe the relative importance of pets' quality versus quantity of life among owners of dogs with heart disease.
Prospective questionnaire-based clinical study.
Owners of 201 dogs with heart disease.
Owners each completed a questionnaire that was designed to ascertain the relative importance of quality versus quantity of life for their pet and to assess the owners' willingness to trade survival time for quality of life, if that were possible. Analyses were performed to evaluate factors associated with owner willingness to trade time for quality of life.
Most owners (170/197 [86%]) were willing to trade survival time for quality of life for their heart disease-affected dogs; of those owners, 88 (52%) were willing to trade 6 months. Owners were highly concerned with detection of perceived pet suffering and their pet's ability to interact with them. Owners whose pets had respiratory difficulty or fainting episodes and were treated on an outpatient basis had a greater willingness to trade survival time than owners of dogs that were treated on an emergency basis. Among owners willing to trade time for quality of life, younger owners and those whose pets had fainting episodes were willing to trade the most amount of time.
Results indicated that quality of life is highly important to owners of dogs with heart disease. Owners' priorities partly depend on owner age and the pet's clinical circumstances; ongoing client-veterinarian communication is important to optimize treatment success as perceived by owners.

0 Followers
 · 
119 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Myxomatous mitral valve disease (MMVD) is an important cause of morbidity and mortality in dogs. To compare, throughout the period of follow-up of dogs that had not yet reached the primary endpoint, the longitudinal effects of pimobendan versus benazepril hydrochloride treatment on quality-of-life (QoL) variables, concomitant congestive heart failure (CHF) treatment, and other outcome variables in dogs suffering from CHF secondary to MMVD. A total of 260 dogs in CHF because of MMVD. A prospective single-blinded study with dogs randomized to receive pimobendan (0.4-0.6 mg/kg/day) or benazepril hydrochloride (0.25-1.0 mg/kg/day). Differences in outcome variables and time to intensification of CHF treatment were compared. A total of 124 dogs were randomized to pimobendan and 128 to benazepril. No difference was found between groups in QoL variables during the trial. Time from inclusion to 1st intensification of CHF treatment was longer in the pimobendan group (pimobendan 98 days, IQR 30-276 days versus benazepril 59 days, IQR 11-121 days; P = .0005). Postinclusion, dogs in the pimobendan group had smaller heart size based on VHS score (P = .013) and left ventricular diastolic (P = .035) and systolic (P = .0044) dimensions, higher body temperature (P = .030), serum sodium (P = .0027), and total protein (P = .0003) concentrations, and packed cell volume (P = .030). Incidence of arrhythmias was similar in treatment groups. Pimobendan versus benazepril resulted in similar QoL during the study, but conferred increased time before intensification of CHF treatment. Pimobendan treatment resulted in smaller heart size, higher body temperature, and less retention of free water.
    Journal of Veterinary Internal Medicine 09/2013; DOI:10.1111/jvim.12181 · 2.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic pain and distress are universally accepted conditions that may adversely affect an animal's quality of life (QOL) and lead to the humane euthanasia of an animal. At most research institutions and zoological parks in the USA, a veterinarian, who has physically examined the animal and reviewed the clinical records, ultimately decides when an animal has reached a humane endpoint. To aid in the difficult process of interpreting pain and distress, we have developed specific behavioural guidelines, in addition to standard clinical information, to help define unique characteristics and traits of primates to assess and promote discussion of an individual primate's QOL, and thereby, to assist in the decision-making process regarding euthanasia. These guidelines advocate the creation of a QOL team when the animal is diagnosed with a life-threatening or debilitating chronic condition, or at the time the animal is entered into a terminal study. The team compiles a list of characteristics unique to that individual animal by utilising a questionnaire and a behavioural ethogram. This list enables the team to quantitatively assess any deviations from the established normal behavioural repertoire of that individual. Concurrently, the QOL team determines the number of behavioural deviations that are needed to trigger an immediate discussion of the necessity for humane euthanasia of the animal. The team remains intact once created, and revisits the animal's condition as frequently as deemed necessary. This process improves animal welfare by continuing the quest to optimally define QOL for captive primates, and potentially for all captive animals.
    Animal welfare (South Mimms, England) 09/2013; 22(4). DOI:10.7120/09627286.22.4.429 · 1.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: atteinte cardiaque s'accompagne souvent de cachexie, facteur pronostique défavorable à l'animal, et parfois même la cause de sa mort. Ainsi, surveiller le statut nutritionnel et adapter la ration alimentaire permettent de conserver la masse maigre et la qualité de vie du chien, ou du chat cardiopathe. Il est recommandé de faire maigrir un animal cardiopathe obèse, car cela améliore sa qualité de vie (toux, fatigue à l'effort). S i l'origine d'une affection cardiaque va-rie d'un animal à l'autre, les conséquen-ces métaboliques sont souvent com-munes et évoluent en fonction de la gravité de l'atteinte organique. ● De façon schématique, la diminution de l'efficacité cardiaque induit une hypoperfu-sion tissulaire, responsable d'une hypoxie et d'une diminution de l'apport en nutri-ments aux cellules. Ces phénomènes entraî-nent des modifications hormonales (insuline, cortisol, catécholamines), responsables d'une augmentation du catabolisme et d'une diminution de l'anabolisme. Ils s'accompagnent également de la produc-tion de cytokines inflammatoires, responsables d'une augmentation des destructions cellulai-res et de la production de radicaux libres. ● L'augmentation de ce stress oxydant conduit à un stress oxydatif par insuffisance des défenses anti-oxydantes de l'orga-nisme. Les radicaux libres ainsi produits et non neutralisés induisent un syndrome in-flammatoire généralisé et une destruction cellulaire [11].

Full-text (2 Sources)

Download
9 Downloads
Available from
Jan 15, 2015